The move is Huntsworth’s first acquisition under the ownership of Clayton, Dubilier & Rice
News
AbbVie and Genmab link for oncology collaboration
AbbVie will pay Genmab $750 million upfront, and potentially up to $3.15 billion in additional development, regulatory and sales milestone payments
Public launch for ICR, CR UK spinout Monte Rosa
The company aims to target cancer with new drugs that take advantage of protein degradation
Lilly signs up for access to Evox’ tech in R&D deal
Evox’ technology modifies exosomes to deliver drugs to areas currently inaccessible
MSD’s Keytruda misses advanced bladder cancer goal
The drug did not significantly improve overall survival or progression free survival in the first-line setting
NHS rolls out new online support for diabetes management
The tools are designed to help people manage their condition during the coronavirus pandemic
Just 13 days left to enter Patient Partnership Index
Less than two weeks remain for UK pharma and biotech companies to enter the Patient Partnership Index 2020
NHS waiting lists could hit 10m by year end
The NHS Confederation also warns that ‘it will not be possible to simply ‘switch on’ NHS services immediately’
Final NHS green light for Roche’s Kadcyla
The drug will be funded as an option for treating patients with HER2-positive early breast cancer
EU expands reach of Vertex’ CF drug Kalydeco
Kalydeco is the only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation
Soleno’s drug misses key goal in Prader-Willi trial
The study failed to meet statistical significance for the primary endpoint, however, it did show a number of other significant benefits
Sanofi hands back rights to Oxford Biomedica gene therapies
The move follows a portfolio review by the French drug giant
Kawasaki-like syndrome linked to coronavirus is new condition
The new condition is called Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS)
NICE rejects Sanofi’s Sarclisa in preliminary guidelines
It is not certain how much more clinical benefit Sarclisa has over existing therapies, the Institute said
EU lockdowns saved more than 3m lives, research indicates
The research also suggests that coronavirus was more infectious than previously estimated
